A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell
A chart showing the percentage of thee market in 2017 made up of standard PCI compared to complex PCI cases. Based on market research from iData.
A chart showing the OCT market based on research from iData.
A chart showing the use of bare-metal stents in the market based on research from iData.

Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and treatment options. Devices for the diagnosis and treatment of CAD can be of high volume and low cost or of a relatively low volume and high cost. The U.S.

In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore concerns about the safety of gadolinium-based contrast agents (GBCAs) and gadolinium retention. The workshop was co-sponsored by NIH, theĀ Radiological Society of North America (RSNA)Ā and the American College of Radiology (ACR).

The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm and coronary artery disease. These conclusions came from late-breaking results from the COMMANDER HF trial presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany, and with simultaneous publication in the New England Journal of Medicine.1

Structural Heart Summit (TVT, LAA, PFO)

Sponsored by CRF

New York Cardiovascular Symposium

Global Cardiology and Cardiologist Meeting

D-HF 2018 Device Therapies for Heart Failure

Subscribe to
Ā© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now